1. ICH. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Quality Guideline Q8(R2) Pharmaceutical Development. 2024. Available from: https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf. Accessed 25 Jan 2024.
2. Debevec V, Srcic S, Horvat M. Scientific, statistical, practical, and regulatory considerations in design space development. Drug Dev Ind Pharm. 2018;44(3):349–64.
3. Thomson NM, Seibert KD, Tummala S, Bordawekar S, Kiesman WF, Irdam EA, Phenix B, Kumke D. Case studies in the applicability of drug substance design spaces developed on the laboratory scale to commercial manufacturing. Org Process Res Dev. 2015;19(8):925–34.
4. Watson TJN, Nosal R, Lepore J, Montgomery F. Misunderstanding Design Space: a Robust Drug Product Control Strategy Is the Key to Quality Assurance. J Pharm Innov. 2018;13(3):283–5.
5. ICH. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Quality Guideline Q12, Technical and Regulatory Considerations for Pharmaceutical Product lifecycle Management. 2024. Available from: https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf. Accessed 25 Jan 2024.